SIR2501, a SARM1 blocker with FDA Fast Track status for chemo nerve damage, gets three poster slots in Washington.

A new review argues that aging has several brakes, not one, and that the way genes are switched may hit the limit first.

Employers get one platform for GLP-1 access, hormone therapy and chronic disease coaching, with clinicians still signing off ...

RoC is recruiting at least 30 pairs of women 40 and older for a 12-week study that pairs skin checks with sleep and stress data.

A Frontiers in Aging perspective pitches encapsulated cells as a steady source of the antiaging protein, framed as a proposed ...

Ultrahuman’s racing partnership is about more than lap times; the bigger story is the teenage years when female healthspan takes shape.

The Swiss drugmaker ends a blood-brain barrier partnership, and BioArctic says the platform itself isn’t the problem.

A late-breaking slot in Boston will bring fresh data on an experimental drug that aims to turn down tau production in the ...

Alamar and Nightingale will hunt rare, low-level proteins in UK Biobank blood for signs of dementia and Parkinson’s long ...

Six-month University of Surrey RCT sees better endothelial function, less arterial stiffness and lower systolic pressure – ...

Emory researchers say a 10-protein plasma signature outperformed the established marker, though it remains a research finding.

A Phase 1 study of MNA-001, which targets TREM2, saw age-linked markers in elderly volunteers shift toward levels seen in ...